











Scott, R. A., Freitag, D. F., Li, L., Chu, A. Y., Surendran, P., Young, R., Grarup, N., Stancakova, 
A., Chen, Y., Varga, T. V. et al.. (2016) A genomic approach to therapeutic target validation 
identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science 
Translational Medicine, 8 (341). 341ra76.  
Permanent WRAP URL: 
http://wrap.warwick.ac.uk/85334  
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions. Copyright © 
and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners. To the extent reasonable and practicable the 
material made available in WRAP has been checked for eligibility before being made 
available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 




A note on versions: 
The version presented here may differ from the published version or, version of record, if 
you wish to cite this item you are advised to consult the publisher’s version. Please see the 
‘permanent WRAP URL’ above for details on accessing the published version and note that 
access may require a subscription. 
 




 Genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R 
variant protective for coronary heart disease 
 
 
All authors with their affiliations appear at the end of this paper. 
 
Author list 
Robert A. Scott,1‡ Daniel F. Freitag,2,3‡ Li Li,4‡§ Audrey Y. Chu,5 Praveen Surendran,2 Robin Young,2 
Niels Grarup,6 Alena Stancáková,7 Yuning Chen,8 Tibor V.Varga,9 Hanieh Yaghootkar,10 Jian'an Luan,1 
Jing Hua Zhao,1 Sara M. Willems,1,11 Jennifer Wessel,12,13 Shuai Wang,8 Nisa Maruthur,14,15,16 Kyriaki 
Michailidou,17 Ailith Pirie,17 Sven J. van der Lee,18 Christopher Gillson,1 Ali Amin Al Olama,17 Philippe 
Amouyel,19 Larraitz Arriola,20,21,22 Dominique Arveiler,23 Iciar Aviles-Olmos,24 Beverley Balkau,25,26 
Aurelio Barricarte,27,22 Inês Barroso,3,28 Sara Benlloch Garcia,17 Joshua C. Bis,29 Stefan Blankenberg,30 
Michael Boehnke,31 Heiner Boeing,32 Eric Boerwinkle,33,34 Ingrid B. Borecki,35 Jette Bork-Jensen,6 
Sarah Bowden,36 Carlos Caldas,37 Muriel Caslake,38 The CVD50 consortium, L. Adrienne Cupples,8,39 
Carlos Cruchaga,40 Jacek Czajkowski,41 Marcel den Hoed,42 Janet A. Dunn,43 Helena M. Earl,44 Georg 
B. Ehret,45 Ele Ferrannini,46 Jean Ferrieres,47 Thomas Foltynie,24 Ian Ford,38 Nita G. Forouhi,1 
Francesco Gianfagna,48,49 Carlos Gonzalez,50 Sara Grioni,51 Louise Hiller,43 Jan-Håkan Jansson,52,53 
Marit E. Jørgensen,54,55 J. Wouter Jukema,56 Rudolf Kaaks,57 Frank Kee,58 Nicola D. Kerrison,1 Timothy 
J. Key,59 Jukka Kontto,60 Zsofia Kote-Jarai,61 Aldi T. Kraja,41 Kari Kuulasmaa,60 Johanna Kuusisto,62,63 
Allan Linneberg,64,65,66 Chunyu Liu,67 Gaëlle Marenne,3 Karen L. Mohlke,68 Andrew P. Morris,69,70 
Kenneth Muir,71,72 Martina Müller-Nurasyid,73,74,75 Patricia B. Munroe,76 Carmen Navarro,77,22 Sune F. 
Nielsen,78 Peter M. Nilsson,79 Børge G. Nordestgaard,78 Chris J. Packard,38 Domenico Palli,80 Salvatore 
Panico,81 Gina M. Peloso,82,83,84 Markus Perola,85,60 Annette Peters,86,75 Christopher J. Poole,87,72 J. 
Ramón Quirós,88 Olov Rolandsson,89 Carlotta Sacerdote,90,91,92 Veikko Salomaa,60 María-José 
Sánchez,93,22 Naveed Sattar ,38 Stephen J. Sharp,1 Rebecca Sims,94 Nadia Slimani,95 Jennifer A. Smith,96 
Deborah J. Thompson,17 Stella Trompet,56 Rosario Tumino,97 Daphne L. van der A,98 Yvonne T. van 
der Schouw,99 Jarmo Virtamo,60 Mark Walker,100 Klaudia Walter,3 GERAD_EC Consortium,† 
Neurology working group Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE), 
Alzheimer's Disease Genetics Consortium,† Pancreatic Cancer Cohort Consortium, EPIC-CVD, EPIC-
InterAct, Jean E. Abraham,101 Laufey T. Amundadottir,102 Jennifer L. Aponte,103§ Adam S. 
Butterworth,2 Josée Dupuis,8 Douglas F. Easton,17,101 Rosalind A. Eeles,61,104 Jeanette Erdmann,105 Paul 
W. Franks,9,53,106 Timothy M. Frayling,10 Torben Hansen,6 Joanna M. M. Howson,2 Torben 
Jørgensen,107,108,109 Jaspal Kooner,110,111,112 Markku Laakso,113 Claudia Langenberg,1 Mark I. 
McCarthy,114,70 James S. Pankow,115 Oluf Pedersen,6 Elio Riboli,116 Jerome I. Rotter,117 Danish 
Saleheen,118 Nilesh J. Samani,119,120 Heribert Schunkert,75,121 Peter Vollenweider,122 Stephen 
O'Rahilly,28,123,124 CHARGE consortium, The CHD Exome+ consortium, CARDIOGRAM Exome 
consortium, Panos Deloukas,125 John Danesh,2,3 Mark O. Goodarzi,126 Sekar Kathiresan,127,128,83 James 
B. Meigs,129,130 Margaret G. Ehm,103 Nicholas J. Wareham,1 Dawn M. Waterworth131  
 
1Medical Research Council Epidemiology Unit, University of Cambridge School of Clinical Medicine, 
Institute of Metabolic Science, Cambridge Biomedical Campus, Cambridge, UK.  
 2 
 
2Department of Public Health and Primary Care, Strangeways Research Laboratory, University of 
Cambridge, Cambridge, UK.  
3The Wellcome Trust Sanger Institute, Cambridge, UK. 
 4Statistical Genetics, Projects, Clinical Platforms & Sciences, GlaxoSmithKline, Research Triangle 
Park, NC, USA.  
5Division of Preventive Medicine, Brigham and Women's Hospital, Boston MA, USA.  
6The Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical 
Sciences, University of Copenhagen, Copenhagen, Denmark.  
7Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.  
8Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA.  
9Department of Clinical Sciences, Genetic and Molecular Epidemiology Unit, Lund University, Malmö, 
Sweden.  
10Genetics of Complex Traits, University of Exeter Medical School, University of Exeter, Exeter, UK.  
11Genetic Epidemiology Unit, Department of Epidemiology, Erasmus University Medical Center, 
Rotterdam, The Netherlands.  
12Fairbanks School of Public Health, Department of Epidemiology, Indianapolis, IN, US.  
13Indiana University School of Medicine, Department of Medicine, Indianapolis, IN, USA.  
14Division of General Internal Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, 
USA.  
15Welch Center for Prevention, Epidemiology, and Clinical Research, Johns Hopkins University, 
Baltimore, Maryland.  
16Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, 
Baltimore, Maryland.  
17Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University 
of Cambridge, Strangeways Laboratory, Worts Causeway, Cambridge, UK.  
18Department of Epidemiology, Erasmus University Medical Center, Rotterdam, Netherlands.  
19University of Lille, Institut national de la santé et de la recherche médicale (Inserm), Centre 
Hospitalier Régional Universitaire de Lille, Institut Pasteur de Lille, UMR1167 - RID-AGE, F-59000 
Lille, France.  
20Public Health Division of Gipuzkoa, San Sebastian, Spain.  
21Instituto BIO-Donostia, Basque Government, San Sebastian, Spain.  
22CIBER Epidemiología y Salud Pública (CIBERESP), Spain.  
 3 
 
23Department of Epidemiology and Public Health (EA3430), University of Strasbourg, Strasbourg, 
France.  
24Sobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.  
25Inserm, Centre de recherche en épidémiologie et santé des populations (CESP), Villejuif, France.  
26Univ Paris-Sud, Villejuif, France.  
27Navarre Public Health Institute (ISPN), Pamplona, Spain.  
28University of Cambridge Metabolic Research Laboratories, Wellcome Trust-MRC Institute of 
Metabolic Science, Cambridge, UK.  
29Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, 
WA, USA.  
30Department of General and Interventional Cardiology, University Heart Center Hamburg, Germany.  
31Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, 
MI, USA.  
32German Institute of Human Nutrition, Potsdam-Rehbruecke, Germany.  
33Human Genetics Center, School of Public Health, University of Texas Health Science Center at 
Houston, Houston, TX, USA.  
34Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.  
35Department of Genetics, Division of Statistical Genomics, Washington University School of 
Medicine, St. Louis, MO, USA.  
36Cancer Research UK Clinical Trials Unit, Institute for Cancer Studies, The University of Birmingham, 
Edgbaston, Birmingham, UK.  
37Cancer Research UK Cambridge Institute and Department of Oncology, Li Ka Shing Centre, 
University of Cambridge, Cambridge, UK.  
38University of Glasgow, Glasgow, UK.  
39National Heart, Lung, and Blood Institute (NHLBI) Framingham Heart Study, Framingham, MA, USA.  
40Dep. of Psychiatry, Washington University, School of Medicine, St. Louis, MO, US.  
41Division of Statistical Genomics, Department of Genetics and Center for Genome Sciences and 
Systems Biology, Washington University School of Medicine, St. Louis, MO, USA.  
42Department of Medical Sciences, Molecular Epidemiology and Science for Life Laboratory, Uppsala 
University, Uppsala, Sweden.  
43Warwick Clinical Trials Unit, University of Warwick, Gibbet Hill Road, Coventry, UK.  
 4 
 
44University of Cambridge and National Institute of Health Research Cambridge Biomedical Research 
Centre at Cambridge University Hospitals National Health Service Foundation Trust, Cambridge, UK.  
45McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, Baltimore, MD, USA.  
46Consiglio Nazionale delle Richerche (CNR) Institute of Clinical Physiology, Pisa, Italy.  
47Department of Epidemiology, UMR 1027- INSERM, Centre Hospitalier Universitaire (CHU) de 
Toulouse, Toulouse, France.  
48Department of Clinical and Experimental Medicine, Research Centre in Epidemiology and 
Preventive Medicine, University of Insubria, Varese, Italy.  
49Department of Epidemiology and Prevention, Istituti di Ricovero e Cura a Carattere Scientifico 
(IRCCS) Istituto Neurologico Mediterraneo Neuromed, Pozzilli, Italy. 
50Catalan Institute of Oncology (ICO), Barcelona, Spain.  
51Epidemiology and Prevention Unit, Milan, Italy.  
52Research Unit, Skellefteå, Sweden.  
53Department of Public Health & Clinical Medicine, Umeå University, Umeå, Sweden.  
54Steno Diabetes Center, Gentofte, Denmark.  
55National Institute of Public Health, Southern Denmark University, Denmark. 
 56Leiden University Medical Center, Leiden, Netherlands.  
57German Cancer Research Centre (DKFZ), Heidelberg, Germany.  
58UK Clinical Research Collaboration (UKCRC) Centre of Excellence for Public Health, Queens 
University Belfast, Northern Ireland, UK.  
59University of Oxford, UK.  
60National Institute for Health and Welfare, Helsinki, Finland.  
61The Institute of Cancer Research, London, UK.  
62Institute of Clinical Medicine, Internal Medicine, University of Eastern Finland, Kuopio, Finland.  
63Kuopio University Hospital, Kuopio, Finland.  
64Research Centre for Prevention and Health, Capital region, Copenhagen, Denmark.  
65Department of Clinical Experimental Research, Rigshospitalet, Glostrup, Denmark.  
66Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of 
Copenhagen, Copenhagen, Denmark.  
67Framingham Heart Study, Population Sciences Branch, NHLBI/NIH, Bethesda, MD, USA.  
 5 
 
68Department of Genetics, University of North Carolina, Chapel Hill, NC, USA.  
69Department of Biostatistics, University of Liverpool, Liverpool, UK.  
70Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.  
71The University of Manchester, Centre for Epidemiology, Institute of Population Health, Oxford 
Road, Manchester, UK.  
72University of Warwick, Coventry, UK.  
73Institute of Genetic Epidemiology, Helmholtz Zentrum München - German Research Center for 
Environmental Health, Neuherberg, Germany.  
74Department of Medicine I, Ludwig-Maximilians-University Munich, Munich, Germany.  
75DZHK (German Centre for Cardiovascular Research), partner site Munich Heart Alliance, Munich, 
Germany.  
76Clinical Pharmacology, William Harvey Research Institute, Barts and The London, Queen Mary 
University of London, London, UK.  
77Department of Epidemiology, Murcia Regional Health Council-IMIB Arrixaca, Murcia, Spain.  
78Department of Clinical Biochemistry, Herlev Hospital, Copenhagen University Hospital, University 
of Copenhagen, Copenhagen, Denmark.  
79Lund University, Malmö, Sweden.  
80Cancer Research and Prevention Institute (ISPO), Florence, Italy.  
81Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.  
82Center for Human Genetic Research, Massachusetts General Hospital, Boston, MA, USA.  
83Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA.  
84Program in Medical and Population Genetics, Broad Institute, Cambridge, MA, USA.  
85Institute of Molecular Medicine Finland (FIMM), University of Helsinki.  
86Institute of Epidemiology II, Helmholtz Zentrum München - German Research Center for 
Environmental Health, Neuherberg, Germany.  
87Department of Medical Oncology, Arden Cancer Centre, University Hospital Coventry and 
Warwickshire.  
88Public Health Directorate, Asturias, Spain.  
89Umeå University, Umeå, Sweden.  
90Unit of Cancer Epidemiology, Citta' della Salute e della Scienza Hospital-University of Turin.  
 6 
 
91Center for Cancer Prevention (CPO), Torino, Italy.  
92Human Genetics Foundation (HuGeF), Torino, Italy.  
93Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs.GRANADA. Hospitales 
Universitarios de Granada/Universidad de Granada, Granada, Spain.  
94Institute of Psychological Medicine and Clinical Neuroscience, MRC Centre, Cardiff University, UK.  
95International Agency for Research on Cancer, Lyon, France.  
96Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.  
97Cancer Registry and Histopathology Unit, "Civic M.P.Arezzo" Hospital, ASP Ragusa (Italy).  
98National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.  
99University Medical Center Utrecht, Utrecht, The Netherlands.  
100Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.  
101Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, 
Strangeways Laboratory, Worts Causeway, Cambridge, UK.  
102Laboratory of Translational Genomics, Division of Cancer Epidemiology and Genetics, National 
Cancer Institute, National Institutes of Health, Bethesda, MD, USA.  
103Genetics, PCPS, GlaxoSmithKline, RTP, NC, USA.  
104Royal Marsden NHS Foundation Trust, Fulham and Sutton, London and Surrey, UK.  
105Institut für Integrative und Experimentelle Genomik, Universität zu Lübeck, Lübeck, Germany.  
106Department of Nutrition, Harvard T. H. Chan School of Public Health, Boston, MA, USA.  
107Research Centre for Prevention and Health, Capital region, Denmark.  
108Department of Public Health, Institute of Health Science, University of Copenhagen, Denmark.  
109Faculty of Medicine, Aalborg University, Denmark.  
110National Heart and Lung Institute, Imperial College London, London, UK.  
111Imperial College Healthcare NHS Trust, London, UK.  
112Ealing Hospital NHS Trust, Middlesex, UK.  
113Department of Medicine, University of Kuopio, Kuopio, Finland.  
114Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), University of Oxford, UK.  
115Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, 
Minneapolis, MN, USA.  
 7 
 
116School of Public Health, Imperial College London, UK.  
117Institute for Translational Genomics and Population Sciences, Los Angeles Biomedical Research 
Institute at Harbor- University of California, Los Angeles (UCLA) Medical Center, Torrance, CA, USA.  
118Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, USA.  
119Department of Cardiovascular Sciences, University of Leicester, Glenfield Hospital, Leicester, UK.  
120National Institute for Health Research (NIHR) Leicester Cardiovascular Biomedical Research Unit, 
Glenfield Hospital, Leicester, UK.  
121Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.  
122Department of Internal Medicine, BH10-462, Internal Medicine, Lausanne University Hospital 
(CHUV), Lausanne, Switzerland.  
123MRC Metabolic Diseases Unit, Cambridge, UK.  
124National Institute of Health Research Cambridge Biomedical Research Centre, Cambridge, UK.  
125William Harvey Research Institute, Barts and The London School of Medicine & Dentistry, Queen 
Mary University of London, UK.  
126Division of Endocrinology, Diabetes and Metabolism, Cedars-Sinai Medical Center, Los Angeles, 
CA, USA.  
127Broad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.  
128Cardiology Division, Center for Human Genetic Research, Massachusetts General Hospital and 
Harvard Medical School, Boston, Massachusetts, USA.  
129Division of General Internal Medicine, Department of Medicine, Massachusetts General Hospital, 
Boston, MA, USA.  
130Department of Medicine, Harvard Medical School, Boston, MA, USA.  
131Genetics, Projects, Clinical Platforms & Sciences, GlaxoSmithKline, Philadelphia, PA, USA.  
‡ These authors contributed equally to the work 
 
† Data used in the preparation of this article were obtained from the Genetic and Environmental 
Risk for Alzheimer’s Disease_Exome Chip (GERAD_EC) Consortium and Alzheimer's Disease Genetics 
Consortium (ADGC). As such, the investigators within the GERAD_EC Consortium and ADGC 
contributed to the design and implementation of GERAD_EC and ADGC and/or provided data but did 
not participate in analysis or writing of this report. 
§ Current affiliation: PAREXEL, Durham, NC 
 
*Correspondence can be addressed to: 
 8 
 
Dawn.M.Waterworth@gsk.com (D. M. W.); robert.scott@mrc-epid.cam.ac.uk (R. A. S.);  
nick.wareham@mrc-epid.cam.ac.uk (N. J. W.) 
 
 
One Sentence Summary: A missense variant in GLP1R associated with lower fasting glucose 
levels and protective against T2D is associated with lower risk of coronary heart disease, 
suggesting that GLP1R agonists are not associated with an unacceptable increase in 
cardiovascular risk.  
 
Abstract 
Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be 
associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to 
inform development of antidiabetic therapies by predicting cardiovascular and other health 
endpoints. We therefore investigated the association of variants in 6 genes that encode drug 
targets for obesity or T2D with a range of metabolic traits in up to 11,806 individuals by targeted 
exome sequencing, and follow-up  in 39,979 individuals by targeted genotyping, with additional in 
silico follow up in consortia. We used these data to first compare associations of variants in genes 
encoding drug targets with the effects of pharmacological manipulation of those targets in clinical 
trials. We then tested the association those variants with disease outcomes, including coronary 
heart disease, to predict cardiovascular safety of these agents. A low-frequency missense variant 
(Ala316Thr;rs10305492) in the gene encoding glucagon-like peptide-1 receptor (GLP1R), the target 
of GLP1R agonists, was associated with lower fasting glucose and lower T2D risk, consistent with 
GLP1R agonist therapies. The minor allele was also associated with protection against heart 
disease, thus providing evidence that GLP1R agonists are not likely to be associated with an 
unacceptable increase in cardiovascular risk. Our results provide an encouraging signal that these 
agents may be associated with benefit, a question currently being addressed in randomised 
controlled trials. Genetic variants associated with metabolic traits and multiple disease outcomes 




In 2008, the US Food and Drug Administration issued guidance for industry on new therapies to treat 
type 2 diabetes (T2D), recommending that sponsors should demonstrate that these treatments are 
“not associated with an unacceptable increase in cardiovascular risk” (1). This mandate challenges 
drug developers to prove safety during clinical trials, which is an expensive and late-phase strategy 
for the identification of such concerns.  Instead, genetic approaches may aid in the identification of 
possible drug side-effects much earlier in the drug development process. Genetic variants can inform 
the treatment and prevention of human disease (2, 3), either reducing the prioritisation of potential 
targets (4, 5) or implicating new targets (6, 7). Functional exonic variants can be useful surrogates for 
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drug effects, when, for example, a loss-of-function (LoF) variant may be a useful tool to understand 
the consequences of pharmacological inhibition of a particular target protein (7). Recent sequencing 
efforts have identified a large number of potentially functional low-frequency and rare exonic 
variants in human populations, even among genes under purifying selection (8–12). Although such 
variants may influence susceptibility to disease, the high cost of these sequencing approaches has 
previously meant that they have not been performed in the sample sizes required to allow routine 
investigation of their association with complex disease and related traits.  
A recent targeted exome sequencing study of 202 genes encoding potential drug targets 
identified an abundance of potentially functional exonic variants (8). Among these 202 genes, six 
genes encoding drug targets licensed or in development by GlaxoSmithKline (GSK) for treatment of 
obesity and/or T2D were included.  Recognizing that these data could be used to test for genetic 
variants mimicking pharmacological manipulation of the encoded protein (drug target), we 
investigated six genes encoding targets of relevance to obesity and T2D. These variants could then 
serve as tools to aid the broader evaluation of drug-related risk for adverse events mediated via on-
target effects.  
As a proof of concept for use of genetic variants to evaluate the cardiovascular safety of 
anti-diabetic agents, we evaluated the widely used glucose-lowering glucagon-like peptide-1 
receptor (GLP1R) agonists (13). These agents are long-acting mimetics of the incretin hormone GLP1, 
which increases insulin secretion after oral consumption of glucose but not after glucose 
administered intravenously. There are uncertainties over the role of these agents in the aetiology of 
rare, adverse pancreatic events that have been reported following their usage (14). These therapies 
have been associated with weight loss (15) and reduced cardiovascular risk factors, and while a 
recent trial reported non-inferiority of GLP1R-agonists in cardiovascular safety(16), multiple trials 
evaluating cardiovascular safety have not yet been completed (17). We used a genetic variant in 
GLP1R that is associated with variation in fasting glucose levels and with T2D risk (18) to evaluate the 
cardiovascular safety of GLP1R agonists. The low-frequency variant protective for T2D was also 
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protective for coronary heart disease (CHD). These findings support the notion that GLP1R agonists 
will not confer an increased cardiovascular risk in people. This study also demonstrates how genetic 
target validation approaches can be employed early in the drug development process to evaluate 
efficacy and safety.  
 
Results 
Association of genetic variants in genes encoding T2D and obesity drug targets  
The study design consisted of initial discovery of variants with suggestive associations, to targeted 
genotyping and in silico follow-up analyses (Fig. 1). We investigated the association of 121 variants in 
six genes encoding therapeutic targets in use or in development for T2D or obesity (CNR2, DPP4, 
GLP1R, SLC5A1, HTR2C, MCHR1)—drawn from a recent targeted exome sequencing study of 202 
genes encoding drug targets (8)—with variation in the following traits: T2D, obesity, body-mass 
index (BMI), waist circumference, fasting glucose, fasting insulin, and 2-h glucose (Fig. 1). In the 
“Discovery Analysis”, we identified seven variants potentially associated with T2D- or obesity-related 
traits (where p<0.001, or which were in a target of interest to GSK and p<0.05) (Table 1).  For these 
seven variants, “Follow-Up Analysis” was performed by targeted genotyping in up to 39,979 
additional individuals of European ancestry.  Where possible, in silico follow-up analysis was 
performed for traits and variants available in large-scale genetic consortia data.  
Initial discovery analyses included 1331 tests of association, with the threshold specified to 
reach significance in combined analyses being p<3.8x10-5. In a combined analysis of results from the 
different phases, we identified a low-frequency (~1% minor allele frequency (MAF)) missense variant 
Ala316Thr; rs10305492 in the GLP1R gene to be associated with fasting glucose (Fig. 2A). The variant 
was in Hardy-Weinberg equilibrium in all genotyped samples (p > 0.2). The effect size (i.e. the 
difference per allele) of 0.09 mM was larger than most common variants previously reported for 
fasting glucose (Fig. 2B), and was recently found to be associated with fasting glucose in non-
overlapping samples from large-scale analyses of coding variant associations with glycaemic traits 
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(18). The combined analysis of the six other variants in Table 1 did not show evidence of association 
(p>3.8x10-5, by linear or logistic regression) with the suggestively associated trait in the discovery 
analysis (“Follow-up” p-values > 0.05; “Combined” p-values > 0.005; Table 1).  
The GLP1R gene encodes the GLP1 receptor, the target for GLP-1, a hormone that mediates 
the augmented response to insulin secretion following oral glucose administration. This receptor is 
the target for the GLP1R-agonist class of T2D therapeutics and the association of this variant with 
fasting glucose mimicked a major effect of this class of agents. To further corroborate the utility of 
this variant as a surrogate indicator of pharmacological modulation of the receptor, we investigated 
its association with T2D and found that the minor allele was associated with lower risk of T2D [odds 
ratio (OR) = 0.83 [0.76, 0.91]; P = 9.4x10-5; in a fixed effect meta-analysis of log-odds ratios from 
studies and consortia listed in table S1 and in Supplementary Materials “Studies contributing to 
follow-up analyses of type-2 diabetes and obesity related traits”; ncases = 25,868, ncontrols = 122,393]. 
However, we saw no association of this GLP1R variant (Ala316Thr; rs10305492) with fasting insulin, 
nor with 2-h glucose (Fig. 2A).  
Although there were no individuals carrying putative LoF variants in GLP1R in the targeted 
sequencing study, a single individual in the cohort-arm of the UK10K study had a LoF allele (W297*) 
but did not have an extreme glycaemic phenotype. This individual’s fasting glucose and insulin 
concentrations were within the range of 95% of the values for this population. Nine high-confidence 
LoF variants in GLP1R were observed in the ExAC database (19). Eight were singletons and the most 
common had a frequency of less than 1/10,000, highlighting the difficulty in restricting analyses to 
individual LoF variants.   
 
Association of GLP1R variant with quantitative traits and comparison with effects observed in 
clinical trials of GLP1R agonists  
To further characterise the extent to which the GLP1R variant associations mirrored the effects of 
GLP1R-agonist therapy, we compared genetic associations to the metabolic effects observed in 
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previously reported clinical trials (Fig. 3, table S2). GLP1R agonist therapy can result in lower fasting 
and post-challenge glucose, weight loss, a reduction in systolic blood pressure, reduced total- and 
LDL-cholesterol and an increase in resting heart rate. The effects of GLP1R-agonists on glycaemic 
measures (fasting glucose and 2-h glucose) were stronger than those on non-glycaemic factors (Fig. 
3), which have been detectable only in some meta-analyses of clinical trials (20–23). 
Using fasting glucose as the benchmark, the per-allele association of the genetic variant with 
glucose (-0.15 SDs [-0.20,-0.11], from Fig. 2) was 3.3-fold weaker than the effect observed for GLP1R-
agonist treatment (-0.49 [-0.60,-0.37], from Fig. 3). We therefore rescaled the genetic associations to 
account for this difference, by multiplying the magnitude of all observed genetic associations by 3.3 
(Fig. 3), and demonstrated that there was little difference between the magnitude of association of 
the GLP1R variant and effects observed in clinical trials beyond that expected by chance (α=0.0025). 
An exception to this observation was the impact of GLP1R agonist therapy on weight in non-diabetic 
individuals when compared to the observed association between the variant and BMI (p=2.6x10-4, 
Cochrane’s Q test) (table S2). The genetic variant was not associated with BMI (Fig. 3), whereas the 
agonist therapy caused a reduction in body mass in non-diabetic individuals but not in individuals 
with T2D (fig. S1, table S2). However, five of the six trials in non-diabetic individuals were performed 
in obese participants (table S3), whose higher starting weight may have enabled a greater weight 
loss.  
GLP1R agonists appeared to have a greater effect on 2-h glucose than the magnitude of 
association observed for the variant (p=2.1x10-12, Cochrane’s Q test) (Fig. 3; fig. S2; table S2). The 
difference was most pronounced in comparison to trials in individuals with T2D, among whom we 
observed heterogeneity in the effect of GLP1R agonists on 2-h glucose, even within drug class 
(I2=97%) (fig. S2B). There was no significant difference between the magnitude of genetic association 
and the impact of GLP1R agonist therapy on 2-h glucose in non-diabetic individuals (Fig. 3; table S2), 
although the number of people included in such trials was much smaller than in trials including 




Association of GLP1R variant with disease outcomes 
Our final aim was to describe the association of the GLP1R variant with CHD and other outcomes. In 
a large-scale international collaboration, we studied 61,846 individuals with CHD and 163,728 
controls, and found that the fasting glucose–lowering allele of GLP1R was associated with protection 
against CHD (Fig. 4). The association with CHD is greater than the 1% reduction in risk that would be 
predicted based on the association of this variant with fasting glucose alone (24) (see Supplementary 
Methods on “Calculating the reduction in coronary heart disease risk attributable to lower fasting 
glucose levels”), suggesting that lowering of fasting glucose alone is unlikely to explain the observed 
association between the GLP1R variant and lower risk of CHD. Although not significant, carriage of 
the minor allele was associated with lower LDL cholesterol, triglycerides, systolic blood pressure, and 
higher HDL cholesterol. 
Using data from international consortia, we found no evidence for association of the GLP1R 
variant with pancreatic cancer, although the confidence intervals were wide owing to the 
comparatively small sample size (4987 cases and 8627 controls) and low frequency of the allele (Fig. 
4). There was no evidence of association with breast, ovarian, or prostate cancer risk. Given the 
interest in GLP1R agonist therapy for neurological disease, including Parkinson’s (25) and 
Alzheimer’s (26), we also investigated the association of the GLP1R variant with those diseases, but 
found no evidence of association (Fig. 4).  
 
Discussion 
Anticipating the side effects of drugs prior to phase III clinical trials could support drug discovery and 
development, reducing attrition rates and saving considerable time and money. The promise of 
human genetics in this endeavour (2, 3, 7, 27) depends on the availability of genetic variants that 
mimic pharmaceutical interventions. We undertook a systematic study to identify such genetic 
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variants in the context of diabetes and obesity, and identified an association between fasting glucose 
and T2D with a missense variant in GLP1R, the gene encoding the GLP-1 receptor—the target of the 
GLP1R agonist class of T2D therapies. Regulatory authorities require evidence that therapies for T2D 
are not associated with unacceptable increases in cardiovascular risk. The reduced risk associated 
with the glucose-lowering genetic variant in GLP1R provides evidence that not only will GLP1R 
agonists meet this regulatory hurdle, but they may also reduce CHD events. Ongoing trials of GLP1R 
agonists are designed to resolve this uncertainty and will also augment the evidence on the broader 
validity of genetic approaches in drug-target validation.  
A key consideration in assessing whether genetic variants can be used to understand 
therapeutic effects is how well the genetic variant mirrors the effects of pharmacological 
intervention at the same target. Genetic association data, here and reported previously (18),  
suggest that lifelong carriage of the minor GLP1R allele (at rs10305492) is associated with lower 
fasting glucose and lower risk of T2D, although not with 2-h glucose. Clinical trial data from 
individuals with T2D, who may have a diminished incretin effect, show that GLP1R agonists lower 2-h 
glucose considerably (28), whereas the effect on 2-h glucose is smaller  in individuals without T2D 
(29), presumably because non-diabetic individuals are less likely to have an impaired incretin effect 
requiring therapeutic correction. Similarly, GLP1R agonists were associated with greater weight loss 
in obese individuals than in non-obese. Such a phenomenon has previously been suggested for the 
effects of GLP1R-agonism on blood pressure, where GLP1R-agonist therapy appears to lower blood 
pressure in individuals with high blood pressure but not in non-hypertensive individuals (30, 31). This 
highlights a limitation in the use of genetic variants in target validation: that the association of 
genetic variants is often tested in individuals of “normal” physiology, whereas clinical trials are 
generally performed in individuals with prevalent disease.  
An important step in evaluating the utility of genomics in target validation is to understand 
the functional consequences of variants. For potential novel targets, whether the variant confers 
gain or loss of function informs the development of either an agonist or antagonist therapy. For 
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example, LoF variants have been used to understand the consequences of antagonism of a novel 
drug target (7, 32). However, researchers have gained insights using variants validated as 
instruments when their phenotypic associations mirrored pharmacological action, even in the 
absence of strong functional insights into the mechanism of those variants (33). GLP1R-agonist 
therapy reduces fasting glucose in humans, as does administration of GLP1, regardless of the 
duration or severity of T2D (34). In mice, the loss of GLP1R leads to fasting hyperglycaemia (35, 36). 
Together, these findings in humans and in mice suggest that the glucose-lowering minor allele at 
rs10305492 confers gain of function. However, differences in basal activity of the human and murine 
GLP1R (37) limit our ability to extrapolate findings from GLP1R knockout mice to humans (15, 32). 
Previous attempts to characterise the effect of this variant in cellular models have been inconclusive 
(38, 39). The rarity of putative LoF alleles in the GLP1R impaired our ability to restrict analyses to 
such variants. Although the absence of definitive functional characterisation is a limitation of this 
study, our observation that the minor allele is strongly associated with lower fasting glucose levels 
and is protective against T2D supports the validity of the variant as a genetic instrument for GLP1R-
agonist therapy. Future integration of large-scale human genetic data with functional 
characterisation in appropriate cell models  will allow broader application of variants, other than 
those characterised as LoF, in target validation.   
Although the GLP1R variant was not associated with any of the other non-glycaemic or 
quantitative cardiovascular parameters, there was insufficient evidence to suggest the genetic 
associations and pharmacological effects were different. Power calculations indicated that, to detect 
the expected association with systolic blood pressure or resting heart rate, a sample size of more 
than 250,000 individuals would be required. This is considerably larger than most current genetic 
consortia, although this limitation could soon be overcome as larger studies become available (40), 
further strengthening the promise of genomics in target validation.  Although we did not observe 
overall evidence for association of variants other than the GLP1R variant, the discovery phase, from 
which we selected variants for follow-up, was relatively small in comparison to the overall sample 
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and there remains a possibility of type II error in the discovery phase. As larger resources of genetic 
data become available, these potential concerns will also be reduced.  
The detection of rare adverse effects of a drug remains a challenge. Pharmaco-
epidemiological approaches using routine database analysis may identify rare adverse outcomes 
associated with treatment, but the approach is rarely conclusive because of confounding, 
particularly by indication. Our demonstration that the GLP1R variant is not associated with 
pancreatic, breast, prostate, or ovarian cancer, or with Parkinson’s or Alzheimer’s disease is limited 
by the upper bounds of the confidence intervals, which are too high to allow strong inference about 
the likely long-term safety of GLP1R agonists with regard to these outcomes. Although these data 
represent the largest resources available globally, the accumulation of studies with greater numbers 
of individuals with genetic data and robust disease outcome classification will considerably enhance 
the potential of this type of investigation. The comparisons of other traits and disease outcomes, 
beyond the primary indications, makes the assumption that pharmacological effects are mediated 
via “on-target” effects and not “off-target” effects (i.e. those mediated by effects of the agent on 
other non-specific targets). Although our results offer insight into the effects of GLP1R agonists, they 
do not necessarily apply to other agents targeting the incretin pathway through different 
mechanisms, such as by DPP-4 inhibition (41). 
In conclusion, through a targeted exome sequencing approach, we identified that a low-
frequency missense variant in GLP1R was associated with lower fasting glucose and risk of T2D, 
similar to the effects of GLP1R agonist therapy. This variant was also associated with lower risk of 
CHD, thus providing supportive evidence that these agents are not likely to be associated with an 
unacceptable increase in cardiovascular risk and may indeed be associated with benefit, a question 
currently being addressed in randomised controlled trials. We propose that future drug 
development and investment decisions could be informed by genomic data much earlier in the 







We studied six genes encoding therapeutic targets licensed or in development for obesity or T2D 
(CNR2, DPP4, GLP1R, SLC5A1, HTR2C, MCHR1), drawn from a recent targeted exome sequencing 
study of 202 genes encoding drug targets (8), which represented approximately 1% of the coding 
genome and 7% of all genes considered current or potential drug targets (8). In the “Discovery 
Analysis”, we investigated the association of common and rare variants in these six genes with seven 
T2D and obesity-related traits (Fig. 1).  We analysed all variants which had i) MAF ≥ 0.5% or well 
imputed (R2 > 0.5) in CoLaus; ii) MAF ≥ 0.5% in GEMS; or iii) MAF ≥ 0.1% in BMI (given the larger 
sample size) in the CoLaus study (42), the GEMS study (43), or all individuals with BMI 
measurements.  We examined 121 variants for association with six traits in the CoLaus study (6*121 
= 726 tests); 4 traits in GEMS (4*121 = 484 tests); and 1 trait in the BMI study, comprising a total of 
1331 tests of association. First, we analysed a subset of the population-based CoLaus study (n=2086) 
for T2D, obesity, waist circumference, fasting glucose, fasting insulin, and 2-h glucose traits. Second, 
in the GEMs dyslipidaemic case and normolipidaemic control study (ncases=787, ncontrols=792), we 
analysed obesity, waist circumference, fasting glucose, and fasting insulin traits.  We performed 
discovery analyses in the CoLaus and GEMS studies separately due to the different study designs and 
traits analysed in attempt to maximise sensitivity to detect associations that might be masked by 
context-dependent associations. Third, BMI measures were available in a larger sample size from 11 
studies (Fig. 1), and were analysed together.   We provide the sample sizes for the discovery analyses 
in Figure 1 and trait-specific sample sizes in Table 1 (n = 505 – 11,806).  We augmented the sequence 
data for the  CoLaus study with imputed data in the remainder of the study (n=3539) where variants 
were imputable (R2>0.5) using a custom imputation process on individuals genotyped on the 




Using results from the discovery analyses, we identified variants that were associated with 
T2D or obesity-related traits at the p<0.001 level or were located in genes encoding targets of 
strategic interest to GSK, including GLP1R, DPP4, CNR2, and HTR2C with a p value threshold of <0.05. 
To maximise sensitivity to detect associations in these genes of highest interest, we took forward to 
follow up those variants reaching p<0.05 in the discovery analyses. However, this did not affect the 
threshold for statistical significance or overall alpha value (3.8x10-5), for which we accounted for all 
association tests performed in the discovery analyses (N=1331). The principal reason for prioritising 
specific genes was to ensure a balance between sensitivity for targets of high priority to GSK and to 
maintain specificity: given that initial replication was performed by de novo large-scale targeted 
genotyping, we were practically unable to follow up vast numbers of variants. This does not bias the 
variants selected for follow-up, nor raise the risk of type I error. Indeed, the only variant we 
determined to be mimicking pharmacological manipulation was well beyond “genome-wide 
significance” even if all possible low-frequency and common variants in the genome had been 
tested. 
We then genotyped seven variants in six genes  in up to 39,979 follow-up participants of 
European ancestry drawn from multiple studies (Fig. 1): CoLaus (when GEMS was the discovery 
sample), GEMS (when CoLaus was the discovery set), Ely (44) (n=1722), EPIC-Norfolk (45) (n=25313), 
Fenland (46) (n=6379), and LOLIPOP (47) (n=6565) studies.  The follow-up analysis of T2D included 
participants from the Norfolk Diabetes Study (Ncases=5587 and Ncontrols=19012) , GenOA study 
(Ncases=129 and Ncontrols=1501), and individuals with T2D from the ADDITION study(48)(Ncases=816) 
who were combined with additional cases from the Ely study (Ncases=116) and compared to non-
diabetic controls from the Ely study (Ncontrols=1487).  
We also sought further in silico follow-up Analysis to further evaluate associations in 
collaborative studies utilizing results from the MAGIC and CHARGE consortia. Five of the seven 
variants were available for in silico analysis (table 1). Further details on each of the studies and 





We carried out genetic association analyses on variants identified via targeted sequencing  using an 
additive genetic model by linear or logistic regression, adjusting for age and sex and other study-
specific covariates. We combined study-specific estimates using fixed effect meta-analysis. We 
performed analyses on standardised variables (mean=0 and SD =1) and, as such, expressed effect 
sizes as standard deviations (SDs) for quantitative traits. In total, we analysed 121 single nucleotide 
variants (SNVs).  Overall, we performed 1,331 tests of association in the discovery analyses and, as 
such, associations that were α<3.8x10-5 in the combined analysis were deemed to be statistically 
significant.   
We performed targeted genotyping of selected variants from discovery analyses using 
Sequenom for the Ely, EPIC-Norfolk, Fenland, and ADDITION studies and KASPar for the LOLIPOP 
study. Imputed data were also available in the GenOA study using reference haplotypes from 
participants in the previous sequencing study (8).   We carried out genetic association analyses in 
each study under an additive genetic model using linear or logistic regression, again adjusting for 
age, sex and study-specific covariates. We sought further in silico follow-up from summary 
association results from MAGIC and CHARGE  consortia (table 1).  We converted summary 
association result effect sizes to SDs using the SD of fasting glucose from the population-based 
Fenland study (SD = 0.65 mM) (46).  We meta-analyzed results from the discovery analysis, follow-up 
analysis and in silico follow-up analysis using a fixed effect, inverse-variance weighted approach. The 
discovery analysis of the CoLaus study included association results from the sequence variants and 
imputed variants (table 1). In the entire CoLaus study, we later directly genotyped (KASPar 
technology) variants which had been imputed in the unsequenced CoLaus participants study as part 
of the original follow-up analysis. The combined analysis results in table 1 therefore represent those 
from the directly genotyped data.  
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For variants that showed statistically significant associations in the combined analysis 
(p<3.8x10-5), we investigated their association with a range of anthropometric, metabolic, and 
cardiovascular risk factors and disease outcomes in the studies described previously , as well as in 
additional studies described in table S1 and S4 and in Supplementary Materials.  We also 
investigated the association of variants reaching statistical significance after follow up (α<3.8x10-5) 
with coronary heart disease (CHD) through targeted genotyping and collaboration with large-scale 
Exome chip consortia (table S1). For these variants, we also investigated association with a range of 
other disease outcomes (table S1), with a particular focus on diseases previously suggested as 
potential opportunities for repositioning (i.e. where existing drugs might be used for alternative 
indications). However, as the variant reaching statistical significance was not well covered on 
existing GWAS arrays or in HapMap, we were limited to those disease outcomes for which we could 
obtain association data. For genes that contained variants with p<3.8x10-5 in the combined analysis, 
we investigated the presence of putative LoF alleles in individuals in whom we had performed 
targeted sequencing (8) and in individuals with whole-genome sequencing from the UK10K study 
(www.uk10k.org).  
 
Comparison of clinical trial effects and genetic associations 
Randomized clinical trials of GLP1R-agonists were identified through previous systematic reviews 
and by performing a supplementary literature search, as detailed in the Supplementary Materials. 
Only trials with placebo or no-drug comparison groups (i.e. no trials with active comparison groups), 
with ≥ 4 weeks drug treatment (i.e. no single dose studies) and ≥ 10 participants per trial arm were 
included. Treatment effects were expressed in SDs before pooling across trials using random effects 
meta-analysis (see table S3 for details of clinical trials included). P-values derived from Cochrane’s Q 
test were used as a guide to assess whether there were pairwise differences between the rescaled 







Table 1. Discovery, follow-up, and combined results for variants taken forward to follow-up. Seven variants in six genes reached p<0.001 (or p<0.05 in 
target of interest to GSK) in sequence-based discovery analyses (Fig. 1) and were taken forward to follow-up in additional samples, by targeted genotyping 
and by in silico lookup from existing consortia. Data and P values are from fixed effect meta-analysis of linear regression for quantitative traits or logistic 
regression for binary disease status. 
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18,937 -0.13 0.04 1.5x10-3 
In silico 
follow-up 
MAGIC (29) 20,077 -0.16 0.03 1.1x10-7- 
Combined   40,883 -0.15 0.02 2.6x10-10 
DPP4 rs56179129 2 162890142 V266I 
Fasting 
glucose 
T C 0.008 Discovery GEMS 1416 0.61 0.21 3.6x10-3 
    
              
Targeted 
follow-up 
CoLaus,ELY,LOLIPOP 12934 0.00 0.07 0.95 
    
              
In silico 
follow-up 
CHARGE Exome chip (18) 49838 0.00 0.03 0.16 
    
              Combined   64188 0.01 0.03 0.71 
SLC5A1 rs200410750 22 32439209 5' UTR 
Fasting 
Glucose 
T C 0.001 Discovery Sequenced and imputed CoLaus 5210 1.44 0.33 1.7x10-5 
    
              
Targeted 
follow-up 
ELY,Fenland,LOLIPOP 12707 -0.16 0.27 0.56 
    
              
In silico 
follow-up 
n/a       NA 
    
              Combined   18059 0.51 0.19 0.01 
CNR2 rs4649124 1 24201357 Synonymous 
2 hour 
glucose 
A G 0.420 Discovery Sequenced and imputed CoLaus 505 0.18 0.06 0.01 
    
              
Targeted 
follow-up 
ELY,Fenland 6377 0.00 0.02 0.95 
    
              
In silico 
follow-up 
MAGIC (proxy: rs10917431)(49)  15234 -0.01 0.01 0.49 
    
              Combined   22106 0.00 0.01 0.88 
CNR2 rs2229579 1 24201162 H316Y T2D T C 0.110 Discovery Sequenced and imputed CoLaus 385/5241 0.73 [0.55,0.97] 0.03 
    
              
Targeted 
follow-up 
ADDITION-Ely, NDS,LOLIPOP,GenOA 7141/27096 1.06 [0.99, 1.14] 0.07 
    
              
In silico 
follow-up 
CHARGE Exome chip (18)  9524/60718 0.96 [0.90, 1.01] 0.10 
    
              Combined   17047/93225 0.99 [0.95, 1.04] 0.67 
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HTR2C rs56372597 X 113951968 Intronic BMI A G 0.150 Discovery BMI 10798 0.05 0.02 2.1x10
-3 
    
              
Targeted 
follow-up 
Additional CoLaus, ELY, EPIC, 
Fenland, LOLIPOP 
36983 0.00 0.01 0.92 
    
              
In silico 
follow-up 
n/a       NA 
    
              Combined   47781 0.01 0.01 0.13 
MCHR1 rs117372135 22 41075523 T25M BMI T C 0.002 Discovery BMI 10952 0.62 0.15 4.5x10
-5 
    





37240 0.08 0.10 0.40 
    
              
In silico 
follow-up 
CHARGE adiposity Exome chip 
working group  
68978 -0.04 0.07 0.59 
    
              Combined   117170 0.08 0.05 0.13 
 
*Analyzed in sequenced CoLaus participants only owing to low imputation quality (R2 < 0.5) in additional CoLaus participants at the discovery stage. #Not 




Figure 1. Overall study design, participating studies, and consortia. Discovery analyses were 
performed using targeted exome sequencing of variation in six genes tested for association with 
seven traits. Variants were taken forward to follow-up by targeted genotyping. Additional in silico 
results were obtained using available association results. Combined results were obtained by fixed-
effect meta-analysis of estimates from linear or logistic regression, as appropriate. Based on the 
1331 statistical tests performed in discovery analyses, p<3.8x10-5 was used as the threshold for 
statistical significance. In targeted genotyping, (g) refers to studies that were directly genotyped for 
relevant markers, whereas (i) indicates those in which relevant variants were captured by 
imputation.  
Figure 2. Association of GLP1R variant (rs10305492) with glycaemic traits. (A) Genetic variant 
association with glycaemic traits. Data are standard deviations per minor allele at rs10305492. 
Fasting glucose results are from the combined analysis (Table 1). Individual studies contributing to 
the associations for fasting insulin and 2-h glucose are in table S4.  All results reflect point estimates 
and 95% confidence intervals (CI) from a fixed-effect meta-analysis of linear regression estimates. (B) 
Effect size of the GLP1R variant (in red) and loci previously reported to be associated with fasting 
glucose. Effect sizes are reported from discovery analyses of available MAGIC results (50), and from 
the combined estimate for the GLP1R variant in (A).  
Figure 3. Comparison of GLP1R variant (rs10305492) associations with effects observed in clinical 
trials of GLP1R agonists in non-diabetic individuals and in individuals with T2D. Genetic 
associations are all scaled to match the effects of GLP1R-agonists on fasting glucose (i.e. per 3.3 
copies of the minor (A) allele). Genetic variant results are beta estimates and 95% confidence 
intervals from fixed effect meta-analysis of linear regression results Trial results are estimates from 
fixed-effect meta-analyses of standardised mean differences between treatment and comparison 
groups of the individual trials listed in table S3. *Trials reported effects on body mass, whereas 
genetic associations were only available for BMI. 
Figure 4. Association of GLP1R variant (rs10305492) with disease outcomes. Association with 
disease outcomes are reported per-minor allele at rs10305492. Data show odds ratios and 95% 
confidence intervals from logistic regression models.  
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Figure S1. Effects of GLP1R agonists on body weight.  
Figure S2. Effects of GLP1R-agonists on 2h glucose. 
Table S1. Study characteristics for disease traits.  
Table S2. Comparison of heterogeneity between trial and rescaled genetic estimates. 
Table S3. Details of randomized trials contributing to analyses of GLP1R-agonist effects 
included in Fig. 2 
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